European School of Haematology (ESH)’s Post

🔬 Exciting Updates from EHA 2024 for the treatment of CLL! 🔬 Prof Dr Dominique Bron, haematologist at the Jules Bordet Institute in Brussels summarizes some of the key results in the field of CLL presented during the 2024 annual EHA meeting: - Zanubrutinib + venetoclax: 100% ORR with 45% complete response in treatment naïve CLL patients with a TP53 mutation. - Monotherapy with epcoritamab leads to an ORR of 62%, with 35% complete responses in a cohort of treatment-naïve and previously treated CLL patients with Richter’s transformation. - A triplet combination of pirtobrutinib, venetoclax and obinutuzumab induced MRD negativity in three quarters of treatment naïve CLL patients. Watch this episode to stay updated on the newest findings in CLL! For all EHA 2024 videos, find the link in the comments! #CLL #Hematology #EHA2024 #MediMix

🚀 Groundbreaking Results for CAR-T Cell Therapy at EHA 2024! Prof Dr Xavier Leleu, Head of the Myeloma Clinic and Department of Haematology at the University Hospital of Poitiers, shared the impressive findings from the KARMMA-2 study. This study showed that idecabtagene vicleucel (ide-cel), a BCMA CAR-T therapy, achieved a 71% complete response rate in high-risk multiple myeloma patients with early relapse. For all EHA 2024 videos, find the link in the comments! 👇 #MediMix #Hematology #CAR_T #MultipleMyeloma #Innovation

Happy to present our data on immunomodulatory drugs (IMiDs), contractile properties of Phospholipase C #PLC, and basic physiology for male #LUTS at this year‘s #EAU24 in #Paris. Data are from our #research group focusing on basic and clinical research in #urological diseases, particularly benign prostatic hyperplasia, voiding dysfunction, prostate cancer, and minimally invasive surgery. Special thanks to Ludwig-Maximilians-Universität München LMU Klinikum München, Department of #Urology for providing the necessary research facilities, and for #funding through the esteemed Ferdinand Eisenberger grant by Deutsche Gesellschaft für Urologie, sponsored by The Janssen Pharmaceutical Companies of Johnson & Johnson, and through Munich Medical and Clinician Scientist Program (MCSP) by Deutsche Forschungsgemeinschaft (DFG) - German Research Foundation. With novel insights gained from basic scientific research, we will provide bench to bedside #translational solutions for the treatment and #care of #LUTS #BPH and #OAB by introducing novel #pharmaceutical options in the #future! #healthcare #research #project #growth #leadership #luts #bph #germany #munich #benchtobedside

We are looking forward to #SNIS2024, where preclinical middle meningeal artery (MMA) embolization study results will be presented. Note the visibility of the #IMPASSembolic in the image below. #neurointerventional #embolization #MMAembolization #subduralhematoma #interventionaloncology #interventionalradiology

Ophthopedia Update:Emerging alternatives to keratoplasty for corneal endothelial cell dysfunction: Purpose of review While effective for treating endothelial dysfunction, keratoplasty has shortcomings including limited access to donor tissue for much of the world. Thus, alternative strategies are under development. This review explores the main advancements achieved in this field during 2022–2023. Recent findings Recent publications further support the validity of intracameral cultivated allogeneic endothelial cell injection and Descemet stripping only, while emphasizing the benefits of adjunctive Rho-associated kinase inhibitor (ROCKi) therapy. New donor-independent artificial implants, such as EndoArt, show favorable results. Multiple pharmacologic agents, especially ROCKi, show promise as monotherapies, yet none are currently approved for human treatment. Multiple regenerative and genetic therapies are being investigated but all are still in preclinical stages. Summary A plethora of innovative alternatives to keratoplasty for endothelial disease is in development. Among these, surgical methods are still the mainstay of treatment and closest to clinical application, though further studies to establish their benefits over keratoplasty are needed. Albeit promising, pharmacologic, regenerative, and genetic approaches require validation and are farther from clinical application. #Ophthalmology #Eye #Ophthotwitter

The rise of personalized medicine is reshaping the pharmaceutical landscape, with 𝟲𝟴% of surveyed physicians already integrating it into their practice. Our research indicates that the market will grow at a CAGR of 𝟭𝟭.𝟰%, driven primarily by oncology, cardiology, and neurology. Despite strong adoption, concerns about costs persist, highlighting the need for affordable solutions. North America and Europe lead the market, while Asia-Pacific shows significant investment in research. As AI and genetic testing gain traction, personalized medicine offers promising growth. Explore our latest insights at GRG Health. https://lnkd.in/gV_DwF5y #PersonalizedMedicine #PharmaTrends #HealthcareInnovation #Genomics #Oncology #Cardiology #AIinHealthcare #MarketResearch #GeneticTesting #GRGHealth Manan Sethi

Acute liver failure (ALF) carries a mortality rate exceeding 40%. While orthotopic liver transplantation stands as the primary clinical recourse, its widespread adoption is hampered by donor scarcity and immunological rejection. This study initially delineates the etiologies and treatment parameters of ALF. It then provides a comprehensive overview of typical nanofiber scaffold fabrication techniques and their applications in modulating the function of liver-related cells and treating ALF. https://lnkd.in/gMxZjpwg #biomedical #tissueengineering

Our latest study published in the Journal of Hematology and Oncology sheds light on the chemical elements impacting adenocarcinoma of the human prostate gland. 🔍 Title: "The Bromine, Calcium, Potassium, Magnesium, Manganese, and Sodium Contents in Adenocarcinoma of Human Prostate Gland" 📝 Abstract: This exploratory study delves into the changes in prostatic tissue levels of key chemical elements in prostate cancer. Researchers found significant alterations in calcium, potassium, magnesium, bromine, manganese, and sodium levels between cancerous and healthy tissues. 🔬 Methodology: Utilizing advanced instrumental neutron activation analysis, the study examined tissue samples from 10 patients with adenocarcinoma and 37 healthy male subjects. 🔬 Key Findings: Bromine and manganese levels were significantly higher in cancerous tissues. Calcium and magnesium levels were notably lower in cancerous tissues. Potassium and sodium levels also showed a decrease in cancerous tissues. 🧠 Implications: The study highlights disruptions in chemical element metabolism in adenocarcinoma-transformed prostate tissue, offering insights into potential avenues for further research and therapeutic interventions. 📖 For more detailed information, check out the full article here: https://lnkd.in/g-WqbYPr Stay informed, stay proactive! 💪 #ProstateCancer #MedicalResearch #ScienceIsKey

🌍 Today is #WorldPsoriasisDay – a reminder of the millions who live with this chronic autoimmune condition and the need for continued advancements in treatment options. At InnoSer, we’re proud to contribute to this mission by offering preclinical research services essential for the study and development of novel psoriasis therapies. Our IL-23 induced research model has become an invaluable tool in advancing our understanding of psoriasis, providing insights into the mechanisms that drive inflammation and skin pathology. Read more about how you can utilize this model in your research here: https://lnkd.in/eT3QZmp9. #WorldPsoriasisDay #PsoriasisResearch #PreclinicalResearch #CRO #InnoSer #LifeSciences #IL23Model #AutoimmuneResearch

🏆 Urologia internationalis award 🏆 by Deutsche Gesellschaft für Urologie at #DGU24 for the discovery of novel concepts of post-receptor signaling: Phospholipase C (PLC) plays an important role in prostate cell proliferation, viability, and cytoskeletal organization (V30.6). Together with our data from small molecule inhibitor #QS11, immunomodulatory imide drugs (#IMiDs), and the contractile properties of PLC in the lower urinary tract, this discovery of potential novel mechanisms of smooth muscle physiology and cellular organization provide the basis for bench to bedside #translational solutions for the #treatment and #care of #LUTS #BPH and #OAB by introducing novel #pharmaceutical options in the #future! Data are from our #research group focusing on basic and translational research in #urologic diseases, in particular lower urinary tract symptoms (LUTS), prostate and bladder #physiology, #urooncology, #prostate, #bladder, and #kidney #cancer, and minimally-invasive #surgery. Shoutout to Prof. Christian Gratzke, Prof. Thomas Bschleipfer, and Prof. Stefan Madersbacher for organizing a perfectly curated session on basic research in LUTS #BPH. Special thanks to Ludwig-Maximilians-Universität München, Department of #Urology for providing the necessary research facilities, and for #funding through Munich Medical and Clinician Scientist Program (MCSP) by Deutsche Forschungsgemeinschaft (DFG) - German Research Foundation, and our industrial partners Johnson & Johnson, APOGEPHA Arzneimittel GmbH, and Tocris Bioscience, a Bio-Techne brand, without whom academic research would not be possible. #healthcare #research #project #growth #leadership #luts #bph #germany #munich #benchtobedside #leipzig #aua #eau #knowledge #academia